CytomX Therapeutics (CTMX) Change in Accured Expenses (2014 - 2026)

CytomX Therapeutics' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 70.89% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.5 million (up 37.78% YoY) and the FY2025 annual result came in at -$3.0 million, up 68.33% from the prior year.
• Change in Accured Expenses was -$3.6 million for Q1 2026 at CytomX Therapeutics, down from $486000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.0 million in Q3 2024 and bottomed at -$7.4 million in Q1 2023.
• A 5-year average of -$1.9 million and a median of -$1.7 million in 2024 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 242.39% in 2023, while the deepest fall reached 932.12% in 2023.
• CytomX Therapeutics' Change in Accured Expenses stood at -$3.9 million in 2022, then jumped by 136.63% to $1.4 million in 2023, then tumbled by 490.03% to -$5.6 million in 2024, then soared by 108.75% to $486000.0 in 2025, then sank by 840.53% to -$3.6 million in 2026.
• Business Quant data shows CTMX's Change in Accured Expenses at -$3.6 million in Q1 2026, $486000.0 in Q4 2025, and -$326000.0 in Q3 2025.